| Literature DB >> 32130795 |
Charlotte K Lautrup1, Keng W Teik2, Ai Unzaki3,4, Shuji Mizumoto5, Delfien Syx6, Heng H Sin7, Irene K Nielsen1, Sara Markholt8, Shuhei Yamada5, Fransiska Malfait6, Naomichi Matsumoto9, Noriko Miyake9, Tomoki Kosho3,10.
Abstract
BACKGROUND: Musculocontractural Ehlers-Danlos Syndrome (mcEDS) is a rare connective tissue disorder caused by biallelic loss-of-function variants in CHST14 (mcEDS-CHST14) or DSE (mcEDS-DSE), both of which result in defective dermatan sulfate biosynthesis. Forty-one patients with mcEDS-CHST14 and three patients with mcEDS-DSE have been described in the literature.Entities:
Keywords: clinical features; delineation; dermatan sulfate; musculocontractural EDS-DSE
Mesh:
Substances:
Year: 2020 PMID: 32130795 PMCID: PMC7216804 DOI: 10.1002/mgg3.1197
Source DB: PubMed Journal: Mol Genet Genomic Med ISSN: 2324-9269 Impact factor: 2.183
Figure 1Clinical photographs of patient 1 at 18 years of age (a−e), patient 2 at 12.5 years of age (f−h), and patient 3 at 21 years of age (i−m)
Figure 2Molecular investigation. (a) Pedigree information and intrafamilial segregation of detected variants in DSE. (b) cDNA structure of DSE and pathogenic variants (mcEDS‐DSE). Untranslated regions (UTRs) are shown as orange bars. The first base and each position of exon‐exon junctions in open reading frames (ORFs) are shown in light blue. Pathogenic variants reported in this study are shown in red characters. ex: exon
Clinical and molecular features of patients with mcEDS‐DSE
| Patient | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | Total ( | mcEDS‐ |
|---|---|---|---|---|---|---|---|---|---|---|
| Family | 1 | 2 | 3 | 4 | 5 | 6 | ||||
| Publication | Müller et al. ( | Syx et al. ( | Schirwani et al. ( | This study | ||||||
| Patient 1 | Patient 2 | Patient 1 | Patient 2 | Patient 3 | ||||||
| Mutation (cDNA) | c.803C>T/homo | c.799A>G/homo | c.1150_1157del/homo | c.1763A>G/homo | c.960T>A/homo | c.996dupT/homo | ||||
| Amino acid change (amino acid) | p.Ser268Leu | p.Arg267Gly | p.Pro384Trpfs*9 | p.His588Arg | p.Tyr320* | p.Val333Cysfs*4 | ||||
| Age at the publication (years) | 2 | 48 | 39 | 33 | 2 | 19 | 14 | 22 | ||
| Sex | M | F | F | M | M | M | F | M | M 5, F 3 | M 22, F 19 |
| Origin | Indian | Spanish | Portuguese | Pakistani | Turkish | Indian | ||||
| Craniofacial | ||||||||||
| Large fontanel with delayed closure (early childhood) | Yes | NR | NR | NR | Yes | Yes | NR | NR | 3/3 (100%) | 23 |
| Small mouth/micro‐retrognathia (infancy) | NR | Yes | Yes | Yes | NR | NR | NR | NR | 3/3 (100%) | |
| Slender face/protruding jaw (from adolescence) | NR | NR | NR | Yes | NR | No | No | Yes | 2/4 (50%) | 11 |
| Facial asymmetricity (from adolescence) | NR | NR | NR | No | NR | Yes | No | No | 1/4 (25%) | 10 |
| Hypertelorism | Yes | Yes | Yes | NR | NR | Yes | Yes | Yes | 6/6 (100%) | 35 |
| Downslanting palpebral fissures | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | 7/8 (88%) | 34 |
| Short palpebral fissures | NR | Yes | Yes | No | Yes | Yes | No | No | 4/7 (57%) | |
| Blue sclera | Yes | Yes | Yes | NR | NR | Yes | Yes | Yes | 6/6 (100%) | 25 |
| Midfacial hypoplasia | NR | Yes | Yes | No | NR | Yes | Yes | Yes | 5/6 (83%) | |
| Short nose with hypoplastic columella | NR | Yes | Yes | No | No | No | No | No | 2/7 (29%) | 16 |
| Ear deformity (e.g. low‐set, posterior rotation, prominent) | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | 7/8 (88%) | 33 |
| Palatal abnormalities (e.g. high, cleft) | Yes | NR | NR | Yes | No | No | Yes | NR | 3/5 (60%) | 25 |
| Long philtrum and/or thin upper lip vermilion | NR | Yes (thin upper lip vermilion) | Yes (both) | No | Yes (thin upper lip vermilion) | No | No | No | 3/7 (43%) | 24 |
| Crowded teeth | Yes | NR | NR | Yes | NR | Yes | NR | NR | 3/3 (100%) | |
| Brachycephaly/flat occiput | Yes | NR | NR | No | Yes | Yes | No | No | 3/6 (50%) | |
| Others | Hypotonic face with wrinkled and saggy eyelids, cheeks, and neck | Prominent forehead | ||||||||
| Skeletal | ||||||||||
| Congenital multiple contractures | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | 7/8 (88%) | 41 |
| Adducted thumbs | Yes (bil) | No | No | Yes (bil) | Yes (bil) | Yes (bil) | No | No | 4/8 (50%) | 33 |
| Talipes equinovarus | Yes (bil) | Yes (bil) | Yes (bil) | Yes (bil) | Yes (bil) | No | No | Yes (bil) | 6/8 (75%) | 41 |
| Recurrent/chronic joint dislocations | NR | No | NR | No | No | Yes (shoulder) | No | No | 1/6 (17%) | 20 |
| Pectus deformilties | NR | NR | NR | NR | No | Yes (mild excavatum) | Yes (excavatum, asymmetric) | Yes (excavatum, asymmetric) | 3/4 (75%) | 18 |
| Spinal deformities | NR | No | Yes (mild to moderate scoliosis) | No | No | Yes (mild lumbar scoliosis) | Yes (scoliosis, thoracic kyphoscoliosis) | Yes (scoliosis) | 4/7 (57%) | 22 |
| Finger shape characteristics | Yes (long, tapering) | Yes (long, slender, tapering) | Yes (long, slender, tapering) | Yes (cylingdrical) | Yes (long, slender) | Yes (long, slender) | Yes (long, slender) | Yes (long, slender) | 8/8 (100%) | 35 |
| Progressive foot deformities | NR | Yes (short, broad feet with short toes) | NR | Yes (wide feet with clawed toes) | Yes | Yes (cavus) | Yes (uni. planus) | Yes (hallux valgus, planus, cavus) | 6/6 (100%) | 26 |
| Marfanoid habitus/slender build | NR | NR | NR | No | NR | No | Yes | Yes | 2/4 (50%) | 13 |
| Joint hypermobility | Yes | Yes | Yes | No | NR | Yes | No | No | 4/7 (57%) | |
| Osteoporosis | NR | NR | NR | NR | NR | NR | Yes | NR | 1/1 (100%) | |
| Others | Joint pain | Chronic pain, brachydactyly, Madelung deformity | Torticollis | Joint pain | Fractures | |||||
| Skin | ||||||||||
| Hyperextensibility | NR | Yes | Yes | No | No | Yes | No | No | 3/7 (43%) | 24 |
| Bruisability | NR | Yes | Yes | NR | Yes | No | No | Yes | 4/6 (67%) | 21 |
| Fragility | NR | Yes | Yes | No | No | No | No | No | 2/7 (29%) | 21 |
| Atrophic scars | Yes | NR | NR | NR | No | No | No | Yes | 2/5 (40%) | |
| Hyperalgesia to pressure | NR | NR | NR | NR | NR | NR | NR | NR | 0/0 (0%) | 8 |
| Fine or acrogeria‐like palmar creases | Yes | Yes | Yes | Yes | No | Yes | Yes | Yes | 7/8 (88%) | 28 |
| Recurrent subcutaneous infections | NR | NR | NR | NR | NR | No | No | No | 0/3 (0%) | 8 |
| Fistula formation | NR | NR | NR | NR | NR | No | No | No | 0/3 (0%) | |
| Delayed wound healing | Yes | NR | NR | NR | NR | Yes | No | No | 2/4 (50%) | |
| Umbilical hernia | NR | NR | NR | NR | NR | Yes | No | No | 1/3 (33%) | |
| Others | Transparent, thin | Transparent, thin | Piezogenic pedal papules | |||||||
| Cardiovascular | ||||||||||
| Congenital heart defects | Yes (PFO) | NR | No | No | Yes (ASD) | Yes (ASD, PDA) | No | NR | 3/6 (50%) | 6 |
| Valve abnormalities | No | Yes (MVP, myxomatous valve with ruptureed chordae, severe MR) | No | No | NR | No | No | NR | 1/6 (17%) | 7 |
| Enlargement of ascending aorta | No | No | No | No | NR | No | No | NR | 0/6 (0%) | 2 |
| Large subcutaneous hematoma | NR | Yes | Yes | NR | No | Yes (elbow, arm, forehead, knee, gluteal region) | NR | Yes (calf) | 4/5 (80%) | 20 |
| Respiratory | ||||||||||
| Pneumothorax/Hemopneumothorax | NR | NR | NR | No | No | No | No | No | 0/5 (0%) | 3 |
| Gastrointestinal | ||||||||||
| Constipation | NR | NR | NR | No | No | Yes | No | No | 1/5 (20%) | 9 |
| Diverticula (e.g. perforation, infection) | NR | NR | NR | No | No | No | No | No | 0/5 (0%) | 4 |
| Others | Eventration after gallbladder surgery | |||||||||
| Urological | ||||||||||
| Nephrolithiasis or cystolithiasis | NR | NR | NR | NR | NR | No | NR | NR | 0/1 (0%) | 7 |
| Hydronephrosis | NR | NR | NR | No | NR | Yes (bil) | NR | NR | 1/2 (50%) | 10 |
| Bladder dysfunction | NR | Yes (prolapse after two deliveries) | NR | NR | NR | No | NR | NR | 1/2 (50%) | 2 |
| Recurrent urinary tract infection | NR | NR | NR | NR | NR | No | NR | NR | 0/1 (0%) | 3 |
| Inguinal hernia | Yes (lt) | NR | Yes | Yes (bil) | NR | Yes (lt) | No | No | 4/6 (67%) | 2 |
| Cryptorchidism in male | NR | Yes | No | Yes (bil) | No | 2/4 (50%) | 17 | |||
| Ophthalmological | ||||||||||
| Strabismus | NR | No | No | No | Yes | Yes (esotropia) | No | No | 2/7 (29%) | 14 |
| Glaucoma or elevated intraocular pressure | NR | No | No | No | No | No | No | No | 0/7 (0%) | 8 |
| Refractive error | NR | No | No | Yes (my) | No | Yes (my) | Yes (as) | Yes (my) | 4/7 (57%) | 16 (hy 4, my 12, as 5) |
| Retinal detachment | NR | No | No | NR | NR | No | No | No | 0/5 (0%) | 6 |
| Otological | ||||||||||
| Hearing impairment | NR | NR | NR | NR | NR | Yes (mild, uni, SNHL for high‐pitched sound) | No | No | 1/3 (33%) | 10 |
| Sexual development‐related | ||||||||||
| Hypogonadism | NR | NR | NR | NR | NR | No | NR | No | 0/2 (0%) | |
| Others | Uterine prolapse after two deliveries | |||||||||
| Central nervous system | ||||||||||
| Ventricular abnormalities (enlargement, asymmetry) | No | NR | NR | NR | No | No | NR | NR | 0/3 (0%) | 8 |
| Hypoplasia of septum pellucidum | No | NR | NR | NR | No | No | NR | NR | 0/3 (0%) | |
| Dandy‐Walker variant | No | NR | NR | NR | No | No | NR | NR | 0/3 (0%) | |
| Muscular system | ||||||||||
| Hypotonia | NR | Yes | Yes | NR | NR | Yes | NR | NR | 3/3 (100%) | 14 |
| Muscle weakness | Yes | Yes | NR | NR | NR | Yes | No | No | 3/5 (60%) | |
| Development | ||||||||||
| Motor developmental delay | Yes | NR | NR | NR | Yes | Yes | No | NR | 3/4 (75%) | 23 |
| Intellectual disabilities | No | NR | NR | No | NR | No | No | Yes | 1/5 (20%) | 4 |
Abbreviations: as, astigmatism; ASD, atrial septal defect; bil, bilateral; F, female; hy, hyperopia; lt, left; M, male; MR, mitral valve regurgitation; MVP, mitral valve prolapse; my, myopia; No, absent; NR, not recorded; PDA, patent ductus arteriosus; PFO, persistent foramen ovale; SNHL, sensorineural hearing loss; uni, unilateral; Yes, present.
Judged from images in the relevant report.
In younger ages but not in adulthood.
Only at the elbows.